The nuclear factor erythroid 2-related factor 2 (Nrf2) has been shown to upregulate BKCa expression by directly binding to the antioxidant response element (ARE) motif of the KCNMA1 promoter, suggesting that treatment with FDA-approved Nrf2 activators may be an effective strategy for enhancing the treatment of coronary artery disease (38). Here, KCNMA1 is linked to coronary artery disorder.